Status:
COMPLETED
Treatment of Coronary Heart Disease With Amiloride
Lead Sponsor:
University of Carabobo
Collaborating Sponsors:
Clinical Research Unit at the Docent Institute of Urology
Northern Metropolitan Hospital
Conditions:
Coronary Heart Disease
Eligibility:
All Genders
35-75 years
Phase:
PHASE2
PHASE3
Brief Summary
Treatment of coronary artery disease is a major health care problem across the entire word, and the United States. Unfortunately, despite a number of medical advances, diagnostic procedure, or epidemi...
Detailed Description
The Problem: Treatment of Cardiovascular Diseases (CVD) is a major health care problem across the entire word, and particularly in the United States, Japan and European Countries (1). In fact, these l...
Eligibility Criteria
Inclusion
- Male or female; age 35-75 years having angina (Canada Cardiovascular Society Class II-IV)
- Essential Hypertension defined as taking at least 1 anti-hypertensive medication, or average systolic blood pressure ≥140 mm Hg, or diastolic blood pressure ≥90 mmHg
- ST-T changes of LVH (Romhilt-Estes or Framingham Heart Study criteria, with typical LV strain pattern, or isoelectric, inverted or biphasic T waves)
- ST-T changes of ischemia in resting ECG (ST depression, isoelectric, biphasic, negative or inverted T-waves)
- Serum potassium \< 5.0 mmol/L prior to randomization
- Negative pregnancy test in child-bearing potential women
- Willing to comply with scheduled visits
- Informed consent form signed by the subject
Exclusion
- Resistance hypertension despite 3-drugs treatment
- Myocardial infarction in past 90 days
- Coronary artery bypass graft surgery in past 90 days
- Atrial fibrillation with a resting heart rate \> 90 bpm
- Percutaneous coronary intervention in past 30 days
- Implanted Pacemaker
- Stroke in past 90 days
- Left or Right Ventricular Branch Block
- Aldosterone antagonist or K sparing drug in last 7 days
- Intolerance to amiloride
- Lithium use
- Current participation in any other therapeutic trial
- Any condition that may prevent the subject from adhering to the trial protocol
- History of hyperkalemia (K ≥5.5 mmol/L) in the past six months or K \>5.0 mmol/L within 2 weeks
- Chronic renal dysfunction
- Liver disease
- Chronic pulmonary disease
- Significant uncorrected valvular heart disease
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2011
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT01231165
Start Date
February 1 2009
End Date
February 1 2011
Last Update
June 11 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hypertension Research Unit
Valencia, Carabobo, Venezuela, 2001